Method and system for evaluating peripheral neuropathy caused by chemotherapy based on numbness analysis

Abstract

The invention belongs to the technical field of evaluation tools, and provides a numbness analysis-based chemotherapy-induced peripheral neuropathy evaluation method and system, and the method comprises the steps: dividing and layering a human body region to obtain a trunk analysis region, an upper limb analysis region, a lower limb analysis region, and a plurality of trunk analysis layers, upper limb analysis layers and lower limb analysis layers which are sequentially arranged; meanwhile, numbness self-evaluation data of the patient is collected and recorded, different positions of the body area of the patient are evaluated according to scoring rules to obtain a numbness self-evaluation score and a wood self-evaluation score corresponding to each analysis layer, and finally, combination processing is performed to obtain a comprehensive scoring result. According to the method and the system for evaluating the chemotherapy-induced peripheral neuropathy based on numbness analysis, quantitative evaluation of numbness and numbness symptoms of a patient can be realized, the sensitivity is high, and regional distribution and dynamic change of numbness parts can be evaluated and fed back, so that the trend of development of the numbness symptoms towards the near end or the far end can be found in time; therefore, the condition of the patient is timely tracked and fed back.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of evaluation tools, and particularly relates to a chemotherapy-induced peripheral neuropathy evaluation method and system based on numbness analysis. BACKGROUND

[0002] Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity reaction of various microtubule inhibitors, platinum, proteasome inhibitors and other antitumor drugs, which usually manifests as symmetrical numbness of hands and feet, paresthesia, pain and movement disorders, etc. Long-term or severe CIPN will affect the quality of life of patients and limit the dosage of chemotherapy, so timely and effective evaluation and treatment of CIPN are crucial for subsequent treatment.

[0003] Due to the complexity of CIPN mechanism and the diversity of symptoms, and the lack of sensitive quantitative tools at present, there are still great challenges in accurately and effectively evaluating CIPN in clinical practice. In recent years, the evaluation method of CIPN has gradually shifted from single physician grading to patient-reported outcomes. Many scales such as EORTC QLQ-CIPN20, FACT / GOG-NTx, CIPNAT (Chemotherapy Induced Peripheral Neuropathy Assessment Tool), PNQ, TNAS, PRO-CTCAE, etc. are widely used in different studies. However, these tools generally have the following deficiencies and shortcomings: (1) Low sensitivity of physician grading, prone to underestimate symptoms: scales such as CTCAE have few items and wide grades, and the scoring of doctors is affected by experience, making it difficult to capture early symptoms, resulting in the phenomenon of underestimating the severity of CIPN by doctors; (2) Patient-reported tools are mostly total scores or single symptom scores: scales such as EORTC QLQ-CIPN20 and FACT / GOG-NTx focus on the average degree of sensory and functional impact, lacking description of the anatomic distribution, development direction and regional changes of symptoms. For example, although TNAS uses a 0-10 scale, it only asks about the degree of numbness and does not record the distribution of numbness and the dynamic changes of the numbness site, such as the dynamic changes of numbness symptoms spreading from the distal to the proximal of the fingers or toes; (3) Pain scores ignore the distinction between "numbness" and "numbness": many tools generally use NRS scores for pain or PRO-CTCAE "pricking" items, but patients often experience symptoms such as needle-like numbness ("numbness") and sensory dullness ("numbness") at the same time. The existing scale tools generally lack the distinction and quantitative scoring of "numbness" and "numbness"; (Four) Lack of attention to the dynamic development and changes of the numb part: Through clinical observation, it is found that CIPN numbness symptoms often start from the distal fingers and toes, and then gradually develop proximally, and the closer the numb part is to the trunk or the higher it is, the more severe the disease usually means. However, the existing scale tools do not record the dynamic changes of the numb part area position, and lack detailed records and assessments of the distribution of the numb part area; It can be seen that the existing evaluation tool scale mostly lacks detailed records and assessments of the nature of the numb and wooden symptoms, the distribution of the numb part area, and the dynamic changes of the numb part. Moreover, most existing studies still use pain scores as a measure of the severity of CIPN, but many patients' main distress is not pain but paresthesia or numbness.

[0004] Therefore, there is a need to design a chemotherapy-induced peripheral neuropathy evaluation method and system that can at least solve the above problems and defects. SUMMARY

[0005] To solve the above technical problems, the present application provides a chemotherapy-induced peripheral neuropathy evaluation method and system based on numbness analysis, which can quantitatively evaluate the numb and wooden symptoms of patients, has high sensitivity, and can evaluate and feedback the regional distribution and dynamic changes of the numb part, so as to timely discover the trend of the numb symptoms developing proximally or distally, and timely track and feedback the patient's condition.

[0006] The technical scheme of the present application is: The present application provides a chemotherapy-induced peripheral neuropathy evaluation method based on numbness analysis, comprising the following steps: dividing the human body into layers to obtain a trunk analysis area , an upper limb analysis area and a lower limb analysis area , the trunk analysis area comprises a plurality of trunk analysis layers arranged from low to high, the upper limb analysis area comprises a plurality of upper limb analysis layers arranged from distal to proximal , and the lower limb analysis area comprises a plurality of lower limb analysis layers arranged from distal to proximal ; collecting and recording patient numbness self-evaluation data, and evaluating different positions of the patient's body area according to the scoring rules to obtain numbness self-evaluation scores and wooden self-evaluation scores corresponding to each analysis layer, the analysis layer comprising all trunk analysis layers , upper limb analysis layers , and lower limb analysis layers ; The score results collected in the above steps are combined to obtain a trunk analysis score , an upper limb analysis score , and a lower limb analysis score . Finally, the analysis score results are combined to obtain a comprehensive score result .

[0007] Preferably, the trunk analysis score is calculated according to the following formula: wherein, is the self-evaluation score of the mth trunk analysis layer at the recording time point, is the weight coefficient of the mth trunk analysis layer, is the self-evaluation score of the mth trunk analysis layer at the recording time point, is the weight coefficient of the mth trunk analysis layer, is the self-evaluation score of the mth trunk analysis layer at the recording time point, is the weight coefficient of the mth trunk analysis layer, is the self-evaluation score of the mth trunk analysis layer at the recording time point, is the weight coefficient of the mth trunk analysis layer, is the self-evaluation score of the mth upper limb analysis layer at the recording time point, is the weight coefficient of the mth upper limb analysis layer, is the self-evaluation score of the mth upper limb analysis layer at the recording time point, is the weight coefficient of the mth upper limb analysis layer, is the self-evaluation score of the mth lower limb analysis layer at the recording time point, is the weight coefficient of the mth lower limb analysis layer, is the self-evaluation score of the mth lower limb analysis layer at the recording time point, is the weight coefficient of the mth lower limb analysis layer, wherein, is the self-evaluation score of the mth trunk analysis layer at the recording time point, is the weight coefficient of the mth trunk analysis layer, is the self-evaluation score of the mth trunk analysis layer at the recording time point, is the weight coefficient of the mth trunk analysis layer, is the self-evaluation score of the mth upper limb analysis layer at the recording time point, is the weight coefficient of the mth upper limb analysis layer, is the self-evaluation score of the mth upper limb analysis layer at the recording time point, is the weight coefficient of the mth upper limb analysis layer, is the self-evaluation score of the mth lower limb analysis layer at the recording time point, is the weight coefficient of the mth lower limb analysis layer, is the self-evaluation score of the mth lower limb analysis layer at the recording time point, is the weight coefficient of the mth lower limb analysis layer, is the self-evaluation score of the mth lower limb analysis layer at the recording time point, is the weight coefficient of the mth lower limb analysis layer, is the self-evaluation score of the mth lower limb analysis layer at the recording time point, is the weight coefficient of the mth lower limb analysis layer, wherein, is the self-evaluation score of the mth trunk analysis layer at the recording time point, is the weight coefficient of the mth trunk analysis layer, is the self-evaluation score of the mth trunk analysis layer at the recording time point, The hemp self-evaluation score, For the Lower limb analysis layer The weight coefficient of the hemp self-evaluation score, At the time of recording Next Lower limb analysis layer The wood self-evaluation score, For the Lower limb analysis layer The weight coefficient of the wood self-evaluation score; The comprehensive scoring results The calculation formula is as follows: in, is the weighting factor for the torso analysis score, is the weight coefficient of the upper limb analysis scoring method, Weighting factors for scoring lower extremity analysis.

[0008] Preferably, the method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis provided by the present invention further comprises the following steps: Statistics at the time of collection and recording All torso analysis layers below Self-evaluation score of hemp The maximum value in and the corresponding serial number , and the self-rating score The maximum value in and the corresponding serial number ; Comparison and as well as and ,like or , it is marked as a worsening of the trunk condition. and , it is marked as the condition of the trunk improved; Statistics at the time of collection and recording All upper limb analysis layers below Self-evaluation score of hemp The maximum value in and the corresponding serial number , and the self-rating score The maximum value in and the corresponding serial number ; Comparison and as well as and ,like or , it is marked as a worsening of the upper limb condition. and , it is marked as the condition of the upper limbs improved; Statistics at the time of collection and recording All lower limb analysis layers below Self-evaluation score of hemp The maximum value in and the corresponding serial number , and the self-rating score The maximum value in and the corresponding serial number ; Comparison and as well as and ,like or , it is marked as a worsening of the lower limb condition. and , it is marked as improvement in the condition of the lower limbs.

[0009] Preferably, the trunk analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with the trunk analysis layer Serial number The values ​​of are positively correlated; The upper limb analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with upper limb analysis layer Serial number The values ​​of are positively correlated; The lower limb analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with lower limb analysis layer Serial number The values ​​of are positively correlated.

[0010] Preferably, the trunk analysis layer Including the left torso analysis layer with symmetrical distribution and right torso analysis layer , the trunk analysis score The calculation formula is as follows: ; The upper limb analysis layer Including the left upper limb analysis layer with symmetrical distribution and right upper limb analysis layer , the upper limb analysis score The calculation formula is as follows: ; The lower limb analysis layer Including the left lower limb analysis layer with symmetrical distribution and right lower limb analysis layer , the lower limb analysis score The calculation formula is as follows: .

[0011] Preferably, the method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis provided by the present invention further comprises the following steps: Statistically merged left torso analysis layer The numbness and numbness self-assessment scores were recorded as the left trunk analysis score. , and the right torso analysis layer The numbness and numbness self-assessment scores were recorded as the right trunk analysis score. , compared with the left trunk analysis score and right trunk analysis score If the absolute value of the difference between the two is less than or equal to the set trunk discrimination parameter, it is marked as symmetrical trunk numbness, otherwise it is marked as lateral trunk numbness; Statistical Merge Left Upper Limb Analysis Layer The numbness and numbness self-assessment scores were recorded as the left upper limb analysis score. , and the right upper limb analysis layer The numbness and numbness self-assessment scores were recorded as the right upper limb analysis scores. , compared with the left upper limb analysis score and right upper limb analysis score If the absolute value of the difference between the two is less than or equal to the set upper limb discrimination parameter, it is marked as symmetrical upper limb numbness, otherwise it is marked as lateral upper limb numbness; Statistical Merge Left Lower Limb Analysis Layer The numbness and numbness self-assessment scores were recorded as the left lower limb analysis score. , and the right lower limb analysis layer The numbness and numbness self-assessment scores were recorded as the right lower limb analysis scores. , compared with the left lower limb analysis score and right lower limb analysis score If the absolute value of the difference between the two is less than or equal to the set lower limb discrimination parameter, it is marked as symmetrical lower limb numbness, otherwise it is marked as lateral lower limb numbness.

[0012] Preferably, the chemotherapy-induced peripheral neuropathy evaluation method based on numbness analysis provided by the present application further comprises collecting sensory data and functional data of the patient through a standardized scale and calculating a scale grading score , wherein the comprehensive score result comprises the scale grading score , and the specific calculation formula is as follows: , wherein, is the weight coefficient of the scale grading score.

[0013] Preferably, the standardized scale comprises any one or more of QLQ-CIPN20 scale, FACT / GOG-NTx scale, CIPNAT scale, PNQ scale, TNAS scale, CAS-CIPN scale, and PRO-CTCAE scale.

[0014] Preferably, the trunk analysis layer comprises a crotch analysis layer , a waist analysis layer , a rib analysis layer , a chest analysis layer , a shoulder analysis layer , and a neck analysis layer . The upper limb analysis layer comprises a finger analysis layer , a palm analysis layer , a wrist analysis layer , a forearm analysis layer , an elbow joint analysis layer , an upper arm analysis layer , and an upper limb root analysis layer . The lower limb analysis layer comprises a toe analysis layer , an arch analysis layer , an ankle analysis layer , a calf analysis layer , a lower leg analysis layer , a knee joint analysis layer , and a thigh root analysis layer .

[0015] Preferably, the present application further provides a chemotherapy-induced peripheral neuropathy evaluation system based on numbness analysis, comprising: a trunk analysis module, configured to divide a human body region into layers to obtain a trunk analysis region comprising a plurality of trunk analysis layers arranged from low to high ​, and analyze several trunk layers according to the scoring rules The corresponding self-assessment score is obtained Hemu self-evaluation score , the above scoring results are combined to obtain the trunk analysis score ; Upper limb analysis module, used to divide the human body into layers and obtain several upper limb analysis layers arranged from far to near. Upper limb analysis area , and analyze several upper limb layers according to the scoring rules The corresponding self-assessment score is obtained Hemu self-evaluation score , the above scoring results are combined to obtain the upper limb analysis score ; The lower limb analysis module is used to divide the human body into layers and obtain several lower limb analysis layers arranged in sequence from far to near. Lower limb analysis area , and analyze several lower limb layers according to the scoring rules The corresponding self-assessment score is obtained Hemu self-evaluation score , the above scoring results are combined to obtain the lower limb analysis score ; Comprehensive analysis module, which processes the torso analysis score obtained by the torso analysis module , Upper limb analysis score obtained through upper limb analysis module , and the lower limb analysis score obtained through the lower limb analysis module Merge and process to get the comprehensive score result .

[0016] The present invention has the following advantages and effects compared to the prior art: (1) Use the trunk analysis area , upper limb analysis area and lower limb analysis area The trunk, upper limbs, and lower limbs are recorded and evaluated separately, and a comprehensive score is obtained by summarizing the results. At the same time, the trunk analysis area, upper limb analysis area, and lower limb analysis area are each provided with several analysis layers arranged in sequence to divide the trunk, upper limbs, and lower limbs into more detailed zone planes, thereby achieving accurate recording and evaluation of the numb area. At the same time, it is easy to find the dynamic changes of the numb area collected at different follow-up recording points, so as to timely detect the changes in the severity of the patient's CIPN; (2) Using the numbness and numbness self-assessment scores collected independently according to the scoring rules, the patients' "numbness" and "numbness" symptoms can be analyzed and evaluated independently, thereby making a more detailed distinction between the nature of the numbness symptoms, facilitating the quantitative assessment of CIPN and improving the sensitivity of the assessment, thereby reducing the risk of underestimating the severity of CIPN; (3) Different weight coefficients were used to weight the numbness self-assessment scores and the numbness self-assessment scores of different position analysis layers, and the regional distribution and dynamic changes of the numbness site were used as influencing factors of the final comprehensive score result, so that the overall comprehensive score result was closer to the patient's numbness symptoms, so that the evaluation results could accurately reflect the severity of CIPN. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Schematic diagram of the structure of human body region division and stratification in the method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis in an embodiment of the present invention; Figure 2 Schematic diagram of another structure for dividing and stratifying human body regions in the method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis in an embodiment of the present invention. DETAILED DESCRIPTION

[0018] In order to make those skilled in the art better understand the present invention, the present invention will be further described in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention and are not intended to limit the present invention.

[0019] Example: The present invention provides a method and system for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis, which specifically includes the following steps: First, see Figure 1 and Figure 2 As shown, the human body area is divided into layers to obtain the trunk analysis area , upper limb analysis area and lower limb analysis area , trunk analysis area Includes several trunk analysis layers arranged from low to high , upper limb analysis area Includes several upper limb analysis layers arranged from far to near , lower limb analysis area Includes several lower limb analysis layers arranged from far to near .

[0020] Specifically, in this embodiment, the trunk analysis layer Including crotch analysis layer , waist analysis layer , rib analysis layer , the chest analysis layer , the shoulder analysis layer , the neck analysis layer ; that is when the serial number corresponds to the hip analysis layer located at the lowest end , when the serial number corresponds to the neck analysis layer located at the highest end .

[0021] upper limb analysis layer including the finger analysis layer , the palm analysis layer , the wrist analysis layer , the forearm analysis layer , the elbow joint analysis layer , the upper arm analysis layer , the upper limb root analysis layer ; that is when the serial number corresponds to the finger analysis layer located at the farthest end , when the serial number corresponds to the upper limb root analysis layer located at the nearest end .

[0022] lower limb analysis layer including the toe analysis layer , the arch analysis layer , the ankle analysis layer , the calf analysis layer , the lower leg analysis layer , the knee joint analysis layer , the thigh root analysis layer ; that is when the serial number corresponds to the toe analysis layer located at the farthest end , when the serial number corresponds to the thigh root analysis layer located at the nearest end .

[0023] It should be noted that, although the above content in the embodiment makes specific description on the number of the trunk analysis layer , the upper limb analysis layer and the lower limb analysis layer , it should not be regarded as a limitation on the number of analysis layers. In actual application, the number of corresponding analysis layers can be adjusted according to clinical data and clinical needs. Here, only a schematic example is made for convenience of explanation and description.

[0024] Then, the patient's self-assessment data of numbness is collected and recorded, and the different locations of the patient's body area are evaluated according to the scoring rules to obtain the corresponding numbness self-assessment scores of each analysis layer. Hemu self-evaluation score , where each analysis layer specifically includes all trunk analysis layers , upper limb analysis layer , lower limb analysis layer In addition, the specific scoring rules refer to the existing pain NRS scoring method, using a 0-10 score for the self-assessment score of numbness and the self-assessment score of numbness to address the shortcomings and defects of existing scale tools that confuse "numbness" and "numbness" or focus only on "pain": Ma self-evaluation score : It is used to assess the degree of tingling, forking, and stinging sensations, where 0 represents no numbness and 10 represents unbearable continuous tingling. Patients self-assess based on their average symptoms in the past 24 hours or the past week. Wood self-evaluation score : It is used to assess the degree of numbness, thick skin feeling, and the feeling of walking on cotton. 0 points represent no numbness and 10 points represent complete loss of sensation. Patients self-assess based on the average symptoms in the past 24 hours or the past week.

[0025] Subsequently, the scoring results collected in the above steps are combined to obtain the torso analysis scores. , upper limb analysis score , and lower limb analysis score Finally, the above analysis and scoring results are combined to obtain the comprehensive scoring result It should be noted that the above analysis scores can be recorded and analyzed separately to achieve independent analysis and evaluation of the trunk, upper limbs, or lower limbs.

[0026] Specifically, trunk analysis score The calculation formula is as follows: in, At the time of recording Next Trunk Analysis Layer The hemp self-evaluation score, For the Trunk Analysis Layer The weight coefficient of the hemp self-evaluation score, At the time of recording Next Trunk Analysis Layer The wood self-evaluation score, For the Trunk Analysis Layer The weight coefficient of the wood self-evaluation score.

[0027] Furthermore, the trunk analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with the trunk analysis layer Serial number The values ​​of are positively correlated, that is, the serial number The larger the value of and The value of also increases accordingly, because the serial number The larger the value, the greater the trunk analysis layer The closer to the high end of the trunk, the higher the trunk analysis layer where numbness symptoms appear, the greater the severity of CIPN. By increasing the corresponding weight coefficient, the final score can be increased to take the regional distribution of numbness into account in the evaluation results, thereby avoiding the underestimation of the severity of CIPN.

[0028] Upper limb analysis score The calculation formula is as follows: in, At the time of recording Next Upper limb analysis layer The hemp self-evaluation score, For the Upper limb analysis layer The weight coefficient of the hemp self-evaluation score, At the time of recording Next Upper limb analysis layer The wood self-evaluation score, For the Upper limb analysis layer The weight coefficient of the wood self-evaluation score.

[0029] Further, the upper limb analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with upper limb analysis layer Serial number The values ​​of are positively correlated, that is, the serial number The larger the value of and The value of also increases accordingly, because the serial number The larger the value, the higher the upper limb analysis layer The closer to the proximal position of the trunk, the more severe the CIPN is. The more numbness symptoms appear in the upper limb analysis layer, the greater the severity of CIPN. By increasing the corresponding weight coefficient, the final score can be increased to take the regional distribution of numbness into account in the evaluation results, thereby avoiding the underestimation of the severity of CIPN.

[0030] Lower limb analysis score The calculation formula is as follows: in, At the time of recording Next Lower limb analysis layer The hemp self-evaluation score, For the Lower limb analysis layer The weight coefficient of the hemp self-evaluation score, At the time of recording Next Lower limb analysis layer The wood self-evaluation score, For the Lower limb analysis layer The weight coefficient of the wood self-evaluation score.

[0031] Further, the lower limb analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with lower limb analysis layer Serial number The values ​​of are positively correlated, that is, the serial number The larger the value of and The value of also increases accordingly, because the serial number The larger the value, the lower limb analysis layer The closer to the proximal position of the trunk, the more severe the CIPN is if numbness occurs in the lower limb analysis layer. By increasing the corresponding weight coefficient, the final score can be increased to take the regional distribution of numbness into account in the evaluation results, thereby avoiding the underestimation of the severity of CIPN.

[0032] Comprehensive scoring results The calculation formula is as follows: in, is the weighting factor for the torso analysis score, is the weight coefficient of the upper limb analysis scoring method, The weight coefficient is used for scoring the lower limbs. It should be noted that the specific values of the weight coefficients 、 、 may be determined and adjusted according to clinical data, clinical experience, and research verification, and will not be described in detail here.

[0033] Further, the peripheral neuropathy evaluation method caused by chemotherapy based on numbness analysis provided in the embodiment further includes the following steps: The maximum value in the self-evaluation score of the numbness of all the trunk analysis layers at the collection time point is recorded as , and the corresponding serial number is recorded as . The maximum value in the self-evaluation score of the numbness of all the trunk analysis layers at the collection time point is recorded as , and the corresponding serial number is recorded as .

[0034] Comparing and and and : If or , it is marked as trunk condition deterioration, which means that at least one of the symptoms of “numbness” or “numbness” appears to dynamically change to a high-end position; If and , it is marked as trunk condition improvement, which means that both the “numbness” symptom and the “numbness” symptom appear to dynamically change to a low-end position.

[0035] It can be understood that since the change of the condition needs time to verify whether it is deterioration or improvement, the above marking is only used as a reference for the dynamic change of the condition at the collection time point and , and it cannot be directly used as a decisive factor affecting the deterioration or improvement of the condition.

[0036] The maximum value in the self-evaluation score of the numbness of all the upper limb analysis layers at the collection time point is recorded as , and the corresponding serial number is recorded as . The maximum value in the self-evaluation score of the numbness of all the upper limb analysis layers at the collection time point is recorded as , and the corresponding serial number is recorded as .

[0037] Comparing and as well as and : like or , it is marked as a worsening of the upper limb condition, which means that at least one of the symptoms of "numbness" or "numbness" has a dynamic change toward the proximal position; like and , it is marked as improvement in the upper limb condition, which means that both the "numbness" and "numbness" symptoms show a trend of dynamic change toward the distal position.

[0038] Statistics at the time of collection and recording All lower limb analysis layers below Self-evaluation score of hemp The maximum value in and the corresponding serial number , and the self-rating score The maximum value in and the corresponding serial number .

[0039] Comparison and as well as and : like or , it is marked as a worsening of the condition of the lower limbs, which means that at least one of the symptoms of "numbness" or "numbness" has a dynamic change trend towards the proximal position; like and , it is marked as improvement in the condition of the lower limbs, which means that both the "numbness" and "woodness" symptoms show a trend of dynamic change toward the distal position.

[0040] Furthermore, the torso analysis layer Including the left torso analysis layer with symmetrical distribution and right torso analysis layer , Trunk Analysis Score The calculation formula is as follows: ; Upper limb analysis layer Including the left upper limb analysis layer with symmetrical distribution and right upper limb analysis layer , upper limb analysis score The calculation formula is as follows: ; Lower limb analysis layer Including the left lower limb analysis layer with symmetrical distribution and right lower limb analysis layer , lower limb analysis score The calculation formula is as follows: .

[0041] Further, the chemotherapy-induced peripheral neuropathy evaluation method based on numbness analysis provided by the embodiment further comprises the following steps: statistics of the numbness self-evaluation score and the numbness self-evaluation score of the left trunk analysis layer are recorded as the left trunk analysis score , and the numbness self-evaluation score and the numbness self-evaluation score of the right trunk analysis layer are recorded as the right trunk analysis score , that is: , , comparison of the left trunk analysis score and the right trunk analysis score , if the absolute value of the difference between the two is less than or equal to the set trunk discrimination parameter, it is marked as trunk numbness symmetry, otherwise it is marked as trunk numbness lateralization, so as to timely find the abnormal situation of the patient, such as lesion lateralization or lesion merger. It should be noted that the trunk discrimination parameter here can be a fixed parameter determined according to clinical data and clinical experience, or it can be adjusted as needed according to the patient's own condition or chemotherapy process, which is not limited here.

[0042] statistics of the numbness self-evaluation score and the numbness self-evaluation score of the left upper limb analysis layer are recorded as the left upper limb analysis score , and the numbness self-evaluation score and the numbness self-evaluation score of the right upper limb analysis layer are recorded as the right upper limb analysis score , that is: , , comparison of the left upper limb analysis score and the right upper limb analysis score , if the absolute value of the difference between the two is less than or equal to the set upper limb discrimination parameter, it is marked as upper limb numbness symmetry, otherwise it is marked as upper limb numbness lateralization, so as to timely find the abnormal situation of the patient, such as lesion lateralization or lesion merger. It should be noted that the upper limb discrimination parameter here can be a fixed parameter determined according to clinical data and clinical experience, or it can be adjusted as needed according to the patient's own condition or chemotherapy process, which is not limited here.

[0043] statistics of the numbness self-evaluation score and the numbness self-evaluation score of the left lower limb analysis layer are recorded as the left lower limb analysis score , and the numbness self-evaluation score and the numbness self-evaluation score of the right lower limb analysis layer are recorded as the right lower limb analysis score ,Right now: , , compared with the left lower limb analysis score and right lower limb analysis score If the absolute value of the difference between the two is less than or equal to the set lower limb discrimination parameter, the lower limb numbness is marked as symmetrical; otherwise, it is marked as lateralized lower limb numbness, so as to promptly detect abnormal conditions such as lesion lateralization or lesion consolidation in patients. It should be noted that the lower limb discrimination parameter here can be a fixed parameter determined based on clinical data and clinical experience, and can also be adjusted as needed based on the patient's own condition or chemotherapy progress. No specific limitation is given here.

[0044] Furthermore, the method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis provided in this embodiment also includes collecting the patient's sensory data and functional data through a standardized scale and calculating the scale grading score. , where the comprehensive scoring results Includes scale rating , the specific calculation formula is as follows: in, The weight coefficient for the scale grading.

[0045] Specifically, the above-mentioned standardized scales include any one or more of the QLQ-CIPN20 scale, FACT / GOG-NTx scale, CIPNAT scale, PNQ scale, TNAS scale, CAS-CIPN scale, and PRO-CTCAE scale. Given that they are mature existing technologies in this field, they will not be described in detail here.

[0046] Optionally, in some embodiments, the present invention further provides a system for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis, which is used to implement the above-mentioned method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis, and specifically includes: The trunk analysis module is used to divide the human body into layers and obtain several trunk analysis layers arranged in order from low to high. Torso Analysis Area , and analyze several trunk layers according to the scoring rules The corresponding self-assessment score is obtained Hemu self-evaluation score , the above scoring results are combined to obtain the trunk analysis score ; Upper limb analysis module, used to divide the human body into layers and obtain several upper limb analysis layers arranged from far to near. Upper limb analysis area , and analyze several upper limb layers according to the scoring rules The numbness self-evaluation score corresponding to the evaluation result is obtained And the wooden self-evaluation score The score results are combined to obtain the upper limb analysis score ; The lower limb analysis module is used for dividing the human body into layers to obtain a lower limb analysis area including a plurality of lower limb analysis layers arranged from far to near The lower limb analysis area According to the scoring rules, a plurality of lower limb analysis layers The numbness self-evaluation score corresponding to the evaluation result is obtained And the wooden self-evaluation score The score results are combined to obtain the lower limb analysis score ; The comprehensive analysis module combines the trunk analysis score obtained by the trunk analysis module The upper limb analysis score obtained by the upper limb analysis module And the lower limb analysis score obtained by the lower limb analysis module Finally, the comprehensive score result is obtained .

[0047] It should be noted that the specific method steps adopted by the trunk analysis module, the upper limb analysis module, the lower limb analysis module and the comprehensive analysis module to realize the corresponding functions can be referred to the content of the chemotherapy-induced peripheral neuropathy evaluation method based on numbness analysis described above, and will not be described in detail here.

[0048] In summary, the chemotherapy-induced peripheral neuropathy evaluation method and system based on numbness analysis provided by the present application can realize quantitative evaluation of the numbness and wooden symptoms of the patient, has high sensitivity, and can evaluate and feedback the regional distribution and dynamic changes of the numbness part, so as to timely discover the trend of the numbness symptoms developing towards the proximal or distal end, and timely track and feedback the patient's condition.

[0049] The above is only the preferred embodiment of the present application, and does not limit the patent scope of the present application, and any equivalent changes and modifications made within the scope of the present application shall still fall within the scope of the present application.

Claims

1. A method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis, characterized in that: The following steps are involved: Divide the human body into layers to obtain the trunk analysis area , upper limb analysis area and lower limb analysis area , the trunk analysis area Includes several trunk analysis layers arranged from low to high , the upper limb analysis area Includes several upper limb analysis layers arranged from far to near , the lower limb analysis area Includes several lower limb analysis layers arranged from far to near ; Collect and record the patient's self-assessment data of numbness, and evaluate different locations of the patient's body according to the scoring rules to obtain the corresponding numbness self-assessment scores for each analysis layer Hemu self-evaluation score , the analysis layer includes all trunk analysis layers , upper limb analysis layer , lower limb analysis layer ; The scoring results collected in the above steps are combined to obtain the torso analysis scores. , upper limb analysis score , and lower limb analysis score Finally, the above analysis and scoring results are combined to obtain the comprehensive scoring result .

2. The method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis according to claim 1, characterized in that: The trunk analysis score The calculation formula is as follows: in, At the time of recording Next Trunk Analysis Layer The hemp self-evaluation score, For the Trunk Analysis Layer The weight coefficient of the hemp self-evaluation score, At the time of recording Next Trunk Analysis Layer The wood self-evaluation score, For the Trunk Analysis Layer The weight coefficient of the wood self-evaluation score; The upper limb analysis score The calculation formula is as follows: in, At the time of recording Next Upper limb analysis layer The hemp self-evaluation score, For the Upper limb analysis layer The weight coefficient of the hemp self-evaluation score, At the time of recording Next Upper limb analysis layer The wood self-evaluation score, For the Upper limb analysis layer The weight coefficient of the wood self-evaluation score; The lower extremity analysis score The calculation formula is as follows: in, At the time of recording Next Lower limb analysis layer The hemp self-evaluation score, For the Lower limb analysis layer The weight coefficient of the hemp self-evaluation score, At the time of recording Next Lower limb analysis layer The wood self-evaluation score, For the Lower limb analysis layer The weight coefficient of the wood self-evaluation score; The comprehensive scoring results The calculation formula is as follows: in, is the weighting factor for the torso analysis score, is the weight coefficient of the upper limb analysis scoring method, Weighting factors for scoring lower extremity analysis.

3. The method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis according to claim 2, characterized in that: The following steps are also included: Statistics at the time of collection and recording All torso analysis layers below Self-evaluation score of hemp The maximum value in and the corresponding serial number , and the self-rating score The maximum value in and the corresponding serial number ; Comparison and as well as and ,like or , it is marked as a worsening of the trunk condition. and , it is marked as the condition of the trunk has improved; Statistics at the time of collection and recording All upper limb analysis layers below Self-evaluation score of hemp The maximum value in and the corresponding serial number , and the self-rating score The maximum value in and the corresponding serial number ; Comparison and as well as and ,like or , it is marked as a worsening of the upper limb condition. and , it is marked as the condition of the upper limbs improved; Statistics at the time of collection and recording All lower limb analysis layers below Self-evaluation score of hemp The maximum value in and the corresponding serial number , and the self-rating score The maximum value in and the corresponding serial number ; Comparison and as well as and ,like or , it is marked as a worsening of the lower limb condition. and , it is marked as improvement in the condition of the lower limbs.

4. The method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis according to claim 2, characterized in that: The trunk analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with the trunk analysis layer Serial number The values ​​of are positively correlated; The upper limb analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with upper limb analysis layer Serial number The values ​​of are positively correlated; The lower limb analysis layer The weight coefficient of the hemp self-evaluation score Weight coefficient of Hemu self-evaluation score Both with lower limb analysis layer Serial number The values ​​of are positively correlated.

5. The method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis according to claim 2, characterized in that: The trunk analysis layer Including the left torso analysis layer with symmetrical distribution and right torso analysis layer , the trunk analysis score The calculation formula is as follows: ； The upper limb analysis layer Including the left upper limb analysis layer with symmetrical distribution and right upper limb analysis layer , the upper limb analysis score The calculation formula is as follows: ； The lower limb analysis layer Including the left lower limb analysis layer with symmetrical distribution and right lower limb analysis layer , the lower limb analysis score The calculation formula is as follows: 。 6. The method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis according to claim 5, characterized in that: The following steps are also included: Statistically merged left torso analysis layer The numbness and numbness self-assessment scores were recorded as the left trunk analysis score. , and the right torso analysis layer The numbness and numbness self-assessment scores were recorded as the right trunk analysis score. , compared with the left trunk analysis score and right trunk analysis score If the absolute value of the difference between the two is less than or equal to the set trunk discrimination parameter, it is marked as symmetrical trunk numbness, otherwise it is marked as lateral trunk numbness; Statistical Merge Left Upper Limb Analysis Layer The numbness and numbness self-assessment scores were recorded as the left upper limb analysis score. , and the right upper limb analysis layer The numbness and numbness self-assessment scores were recorded as the right upper limb analysis scores. , compared with the left upper limb analysis score and right upper limb analysis score If the absolute value of the difference between the two is less than or equal to the set upper limb discrimination parameter, it is marked as symmetrical upper limb numbness, otherwise it is marked as lateral upper limb numbness; Statistical Merge Left Lower Limb Analysis Layer The numbness and numbness self-assessment scores were recorded as the left lower limb analysis score. , and the right lower limb analysis layer The numbness and numbness self-assessment scores were recorded as the right lower limb analysis scores. , compared with the left lower limb analysis score and right lower limb analysis score If the absolute value of the difference between the two is less than or equal to the set lower limb discrimination parameter, it is marked as symmetrical lower limb numbness, otherwise it is marked as lateral lower limb numbness.

7. The method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis according to claim 2, characterized in that: It also includes collecting sensory and functional data from patients through standardized scales and calculating scale grading scores. , the comprehensive scoring result Contains the scale rating score , and its specific calculation formula is as follows: in, The weight coefficient for the scale grading.

8. The method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis according to claim 7, characterized in that: The standardized scales include any one or more of the QLQ-CIPN20 scale, the FACT / GOG-NTx scale, the CIPNAT scale, the PNQ scale, the TNAS scale, the CAS-CIPN scale, and the PRO-CTCAE scale.

9. The method for evaluating chemotherapy-induced peripheral neuropathy based on numbness analysis according to claim 1, characterized in that: The trunk analysis layer Including hip analysis layer, waist analysis layer , rib analysis layer , chest analysis layer , shoulder analysis layer , neck analysis layer ; The upper limb analysis layer Including finger analysis layer , palm analysis layer , wrist analysis layer, forearm analysis layer , elbow joint analysis layer , upper arm analysis layer , upper limb root analysis layer ; The lower limb analysis layer Including toe analysis layer , arch analysis layer , ankle analysis layer , calf analysis layer , calf analysis layer , knee joint analysis layer , thigh root analysis layer .

10. A chemotherapy-induced peripheral neuropathy assessment system based on numbness analysis, characterized in that: include: The trunk analysis module is used to divide the human body into layers and obtain several trunk analysis layers arranged in order from low to high. Torso Analysis Area , and analyze several trunk layers according to the scoring rules The corresponding self-assessment score is obtained Hemu self-evaluation score , the above scoring results are combined to obtain the trunk analysis score ; Upper limb analysis module, used to divide the human body into layers and obtain several upper limb analysis layers arranged from far to near. Upper limb analysis area , and analyze several upper limb layers according to the scoring rules The corresponding self-assessment score is obtained Hemu self-evaluation score , the above scoring results are combined to obtain the upper limb analysis score ; The lower limb analysis module is used to divide the human body into layers and obtain several lower limb analysis layers arranged in sequence from far to near. Lower limb analysis area , and analyze several lower limb layers according to the scoring rules The corresponding self-assessment score is obtained Hemu self-evaluation score , the above scoring results are combined to obtain the lower limb analysis score ; Comprehensive analysis module, which processes the torso analysis score obtained by the torso analysis module , Upper limb analysis score obtained through upper limb analysis module , and the lower limb analysis score obtained through the lower limb analysis module Merge and process to get the comprehensive score result .

Images